AstraZeneca said on Thursday its experimental drug Tezspire met all primary and secondary goals in a late-stage clinical trial evaluating the treatment for eosinophilic esophagitis, a chronic inflammatory condition.
The phase 3 trial assessed Tezspire’s efficacy and safety in patients with the condition, which is characterized by inflammation of the esophagus and symptoms including difficulty swallowing. The drug targets thymic stromal lymphopoietin (TSLP), a protein implicated in triggering inflammation associated with eosinophilic disorders and severe asthma.
Results showed Tezspire significantly reduced esophageal inflammation compared with placebo and improved both the frequency and severity of swallowing difficulties among participants. The trial’s success marks a potential advancement in addressing an underserved patient population with limited treatment options.
Tezspire is a monoclonal antibody developed in partnership between AstraZeneca and Amgen. The companies have not yet disclosed regulatory filing timelines following the trial’s positive outcome.
